TWI485161B - 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 - Google Patents

抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 Download PDF

Info

Publication number
TWI485161B
TWI485161B TW102107344A TW102107344A TWI485161B TW I485161 B TWI485161 B TW I485161B TW 102107344 A TW102107344 A TW 102107344A TW 102107344 A TW102107344 A TW 102107344A TW I485161 B TWI485161 B TW I485161B
Authority
TW
Taiwan
Prior art keywords
epcam
antibody
cells
cell
binding fragment
Prior art date
Application number
TW102107344A
Other languages
English (en)
Chinese (zh)
Other versions
TW201350507A (zh
Inventor
吳漢忠
廖美英
林政緯
Original Assignee
中央研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中央研究院 filed Critical 中央研究院
Publication of TW201350507A publication Critical patent/TW201350507A/zh
Application granted granted Critical
Publication of TWI485161B publication Critical patent/TWI485161B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
TW102107344A 2012-03-02 2013-03-01 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 TWI485161B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261606220P 2012-03-02 2012-03-02

Publications (2)

Publication Number Publication Date
TW201350507A TW201350507A (zh) 2013-12-16
TWI485161B true TWI485161B (zh) 2015-05-21

Family

ID=49083343

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102107344A TWI485161B (zh) 2012-03-02 2013-03-01 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法

Country Status (6)

Country Link
US (1) US9187558B2 (https=)
EP (1) EP2819695B1 (https=)
JP (1) JP6163502B2 (https=)
CN (1) CN104168916B (https=)
TW (1) TWI485161B (https=)
WO (1) WO2013131001A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998932B (zh) 2011-06-29 2017-06-06 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
WO2015153816A2 (en) 2014-04-01 2015-10-08 Academia Sinica Methods and systems for cancer diagnosis and prognosis
US11098131B2 (en) 2015-07-31 2021-08-24 Sutro Biopharma, Inc. Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies
ES2873846T5 (en) * 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
US20190262397A1 (en) 2016-07-26 2019-08-29 Tessa Therapeutics Pte. Ltd. Chimeric antigen receptor
JP6433951B2 (ja) * 2016-08-09 2018-12-05 東芝デジタルソリューションズ株式会社 ネットワーク監視装置およびプログラム
US10787499B2 (en) 2017-02-13 2020-09-29 Regents Of The University Of Minnesota EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20210324335A1 (en) * 2018-09-04 2021-10-21 Academia Sinica Medium composition and method for culturing mesenchymal stem cells
JP7566766B2 (ja) * 2019-03-11 2024-10-15 ヤンセン バイオテツク，インコーポレーテツド 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
AU2020292304B2 (en) * 2019-06-11 2023-03-30 Bioatla, Inc. Conditionally active anti-EpCam antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112022009259A2 (pt) * 2019-11-14 2022-08-02 Academia Sinica Métodos para tratar, inibir ou eliminar um câncer em um indivíduo
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
CN113527491B (zh) * 2020-08-19 2023-06-20 苏州易慕峰生物科技有限公司 人源化抗体、嵌合抗原受体、核酸、载体、细胞及应用
EP4263601A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC Epcam binding molecules and uses thereof
TWI754504B (zh) * 2020-12-25 2022-02-01 龍華科技大學 棉花棒棒體之膠體檢測系統及其檢測方法
CA3221816A1 (en) * 2021-06-25 2022-12-29 Han-Chung Wu Combined cancer therapy with an epithelial cell adhesion molecule (epcam) inhibitor and a hepatocyte growth factor receptor (hgfr) inhibitor
WO2022272050A1 (en) * 2021-06-25 2022-12-29 Academia Sinica Combined cancer therapy with an epithelial cell adhesion molecule (epcam) inhibitor and a wnt inhibitor
JP7794605B2 (ja) * 2021-11-05 2026-01-06 シスメックス株式会社 抗体の製造方法及び抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092491A1 (en) * 2007-04-04 2010-04-15 Anna Anastasi Anti-epcam antibody and uses thereof
TW201125583A (en) * 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
DE60038132T2 (de) * 1999-12-27 2009-04-02 Crucell Holland B.V. Antikörper gegen Ep-Cam
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2004106917A2 (de) * 2003-06-02 2004-12-09 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Verfahren zur selektion von epitopen zur immuntherapie
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
WO2007008943A2 (en) * 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
JP2011193728A (ja) * 2008-07-17 2011-10-06 Murata Mfg Co Ltd ＥｐＣＡＭに結合能を有するペプチド
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
AU2010295172B2 (en) 2009-09-21 2016-08-04 Ranju Ralhan Methods and compositions for the diagnosis and treatment of thyroid cancer
SG185100A1 (en) * 2010-05-04 2012-11-29 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092491A1 (en) * 2007-04-04 2010-04-15 Anna Anastasi Anti-epcam antibody and uses thereof
TW201125583A (en) * 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P Ruf et al, Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer, British Journal of Cancer (2007) 97, 315 – 321 *

Also Published As

Publication number Publication date
WO2013131001A1 (en) 2013-09-06
EP2819695A4 (en) 2016-01-20
TW201350507A (zh) 2013-12-16
CN104168916B (zh) 2017-07-04
US20150017230A1 (en) 2015-01-15
CN104168916A (zh) 2014-11-26
EP2819695B1 (en) 2018-06-27
EP2819695A1 (en) 2015-01-07
JP6163502B2 (ja) 2017-07-12
US9187558B2 (en) 2015-11-17
JP2015517982A (ja) 2015-06-25

Similar Documents

Publication Publication Date Title
TWI485161B (zh) 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
US9670287B2 (en) Anti-human TROP-2 antibody having anti-tumor activity in vivo
KR102159773B1 (ko) 글리피칸-3에 대한 고친화력 단클론 항체 및 이의 용도
EP2096122B1 (en) Anti-human dlk-1 antibody showing anti-tumor activity in vivo
US8017118B2 (en) Anti-hDlk-1 antibody having an antitumor activity in vivo
JPWO2014054820A1 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
HK1198042A (en) Anti-human trop-2 antibody exhibiting antitumor activity in vivo
NZ623464B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
HK1198042B (en) Anti-human trop-2 antibody exhibiting antitumor activity in vivo
NZ716839A (en) Anti-human trop-2 antibody having an antitumor activity in vivo
NZ716839B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo